Welcome to our dedicated page for Visionary Holdings news (Ticker: GV), a resource for investors and traders seeking the latest updates and insights on Visionary Holdings stock.
Visionary Holdings Inc. (Nasdaq: GV) generates news at the intersection of education, health management, anti-aging medical aesthetics, and regenerative medicine. Company announcements describe an ongoing strategic transformation from a traditional education- and real estate-focused business toward a diversified platform centered on high-end medical aesthetics and big health technology, with AI-enabled education remaining as a supplementary division.
News coverage for GV includes updates on its fiscal year 2025 annual report, where the company outlined progress in its business restructuring and reported initial revenue contributions from emerging health-related businesses. Releases also detail Visionary Holdings' focus on health management initiatives, including gastrointestinal health management and early-stage commercialization efforts in Asia.
Another key stream of news relates to regenerative medicine and stem cell technology. Visionary Holdings has reported a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd., the creation of Visionary Yike Stemcell Technologies Inc. in Canada, and the launch of a stem cell-based anti-aging product line through its Visionary Health Technology Group Limited subsidiary. These items highlight the company’s emphasis on stem cell therapy, cellular rejuvenation, and premium anti-aging offerings in Asian markets.
Governance and compliance developments are also prominent in GV’s news. The company has announced board renewal, the formation of specialized committees, leadership changes, and auditor appointments, as well as a Nasdaq notification regarding a delayed Form 20-F filing and its plan to regain compliance. Additional releases describe Visionary Holdings’ controlling stake in a joint venture focused on Traditional Chinese Medicine health preservation.
Investors and observers reviewing GV news can expect updates on strategic partnerships, joint ventures, product launches in anti-aging and regenerative medicine, governance changes, and disclosures related to its education and health businesses.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Goldfield has successfully completed a cash tender offer for all outstanding shares at $7.00 per share, with 73.83% of shares tendered. This allows First Reserve to merge with Goldfield without additional shareholder votes. Upon completion, Goldfield will become a wholly owned subsidiary, and its common stock will cease trading on the NYSE American. The merger is anticipated to finalize today.
On December 22, 2020, First Reserve Fund XIV, L.P. announced a waiver of the "Inside Date Condition" related to its all-cash tender offer for The Goldfield Corporation's common stock. The offer is set at $7.00 per share and will expire on December 29, 2020, at 11:59 P.M. NYC time. All other terms of the tender offer remain unchanged. Innisfree M&A Incorporated and American Stock Transfer & Trust Company are involved as information agent and paying agent, respectively. Investors are encouraged to review the filed tender offer materials with the SEC.
First Reserve Fund XIV, L.P. has commenced a cash tender offer for all outstanding shares of The Goldfield Corporation (GV) at $7.00 per share, valuing the deal at approximately $194 million. This tender offer provides a 57% premium over Goldfield's 30-day average price of $4.46 as of November 23, 2020. The offer is conditioned on a majority of Goldfield's outstanding shares being tendered by December 29, 2020. Following the tender offer, Goldfield will become a wholly owned subsidiary of First Reserve, ceasing to be publicly traded.
Goldfield Corporation (NYSE American: GV) has entered into a definitive merger agreement with an affiliate of First Reserve. The agreement stipulates that First Reserve will acquire all outstanding shares of Goldfield for $7.00 per share, representing a 64% premium to the stock's closing price on November 23, 2020. This agreement, unanimously approved by Goldfield's Board of Directors, implies a total enterprise value of approximately $194 million. The transaction is set to close by January 2021, pending regulatory approvals and minimum tender conditions.